Bain Capital Life Sciences Investors 13F annual report

Bain Capital Life Sciences Investors is an investment fund managing more than $895 million ran by Adam Koppel. There are currently 32 companies in Mr. Koppel’s portfolio. The largest investments include SpringWorks Therapeutics and Nuvalent Inc, together worth $232 million.

Limited to 30 biggest holdings

$895 million Assets Under Management (AUM)

As of 7th February 2023, Bain Capital Life Sciences Investors’s top holding is 4,831,307 shares of SpringWorks Therapeutics currently worth over $126 million and making up 14.0% of the portfolio value.Relative to the number of outstanding shares of SpringWorks Therapeutics, Bain Capital Life Sciences Investors owns less than approximately 0.1% of the company.In addition, the fund holds 3,577,267 shares of Nuvalent Inc worth $107 million. The third-largest holding is Newamsterdam Pharma Company worth $90.5 million and the next is Natera Inc worth $56.2 million, with 1,400,000 shares owned.

Currently, Bain Capital Life Sciences Investors's portfolio is worth at least $895 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Bain Capital Life Sciences Investors

The Bain Capital Life Sciences Investors office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Adam Koppel serves as the Partner of Bain Capital Life Sciences Investors, LLC at Bain Capital Life Sciences Investors.